Myelodysplastic Syndrome (MDS) Clinical Trial
Official title:
An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients. The study also aims to determine an appropriate safe dose of treosulfan, when patient's renal function is impaired. The participants of this study are undergoing allogenic hematopoietic stem cell transplantation for treatment of acute myeloid leukemia or myelodysplastic syndrome.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02626715 -
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
|
Phase 2 | |
| Recruiting |
NCT02905552 -
Myelodysplasic Syndromes and Risk Factors for Infection
|
N/A | |
| Completed |
NCT01772953 -
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
|
Phase 2 | |
| Suspended |
NCT01211691 -
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT06294275 -
A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT00533416 -
Safety of ON 01910.Na in Patients With Myelodysplasia
|
Phase 1 | |
| Active, not recruiting |
NCT04401748 -
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
|
Phase 3 | |
| Recruiting |
NCT04608110 -
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
|
Phase 1 | |
| Recruiting |
NCT03613532 -
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
|
Phase 1 | |
| Withdrawn |
NCT03486353 -
A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
|
Phase 2 | |
| Terminated |
NCT02259348 -
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
|
Phase 2 | |
| Terminated |
NCT01459159 -
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
|
Phase 2 | |
| Terminated |
NCT01422486 -
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
|
Phase 2 | |
| Terminated |
NCT00542828 -
Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome
|
Phase 2 | |
| Completed |
NCT01685619 -
AML-MDS Novel Prognostic Tests Clinical Study
|
||
| Recruiting |
NCT01861093 -
Safety Study of Cord Blood Units for Stem Cell Transplants
|
Phase 2 | |
| Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01758042 -
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
|
N/A | |
| Completed |
NCT01338337 -
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
|
Phase 2 | |
| Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 |